Logo image of ALXO

ALX ONCOLOGY HOLDINGS INC (ALXO) Stock Fundamental Analysis

USA - NASDAQ:ALXO - US00166B1052 - Common Stock

1.57 USD
+0.03 (+1.95%)
Last: 11/3/2025, 8:00:00 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ALXO. ALXO was compared to 534 industry peers in the Biotechnology industry. ALXO may be in some trouble as it scores bad on both profitability and health. ALXO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ALXO had negative earnings in the past year.
In the past year ALXO has reported a negative cash flow from operations.
In the past 5 years ALXO always reported negative net income.
In the past 5 years ALXO always reported negative operating cash flow.
ALXO Yearly Net Income VS EBIT VS OCF VS FCFALXO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

ALXO's Return On Assets of -122.30% is on the low side compared to the rest of the industry. ALXO is outperformed by 79.96% of its industry peers.
ALXO has a Return On Equity of -180.97%. This is in the lower half of the industry: ALXO underperforms 65.17% of its industry peers.
Industry RankSector Rank
ROA -122.3%
ROE -180.97%
ROIC N/A
ROA(3y)-65.92%
ROA(5y)-46.28%
ROE(3y)-83.34%
ROE(5y)-56.97%
ROIC(3y)N/A
ROIC(5y)N/A
ALXO Yearly ROA, ROE, ROICALXO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALXO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALXO Yearly Profit, Operating, Gross MarginsALXO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, ALXO has more shares outstanding
The number of shares outstanding for ALXO has been increased compared to 5 years ago.
ALXO has a worse debt/assets ratio than last year.
ALXO Yearly Shares OutstandingALXO Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ALXO Yearly Total Debt VS Total AssetsALXO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

ALXO has an Altman-Z score of -11.62. This is a bad value and indicates that ALXO is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -11.62, ALXO is not doing good in the industry: 75.28% of the companies in the same industry are doing better.
ALXO has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of ALXO (0.13) is worse than 65.36% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Altman-Z -11.62
ROIC/WACCN/A
WACCN/A
ALXO Yearly LT Debt VS Equity VS FCFALXO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 4.52 indicates that ALXO has no problem at all paying its short term obligations.
ALXO has a Current ratio of 4.52. This is comparable to the rest of the industry: ALXO outperforms 50.56% of its industry peers.
ALXO has a Quick Ratio of 4.52. This indicates that ALXO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.52, ALXO is in line with its industry, outperforming 51.87% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.52
Quick Ratio 4.52
ALXO Yearly Current Assets VS Current LiabilitesALXO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 41.21% over the past year.
EPS 1Y (TTM)41.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ALXO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.65% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y31.87%
EPS Next 2Y25.81%
EPS Next 3Y17.91%
EPS Next 5Y23.65%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALXO Yearly Revenue VS EstimatesALXO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2030 2031 2032 20M 40M 60M 80M 100M
ALXO Yearly EPS VS EstimatesALXO Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 -4 6 8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALXO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALXO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALXO Price Earnings VS Forward Price EarningsALXO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALXO Per share dataALXO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

ALXO's earnings are expected to grow with 17.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.81%
EPS Next 3Y17.91%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALXO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALX ONCOLOGY HOLDINGS INC

NASDAQ:ALXO (11/3/2025, 8:00:00 PM)

1.57

+0.03 (+1.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-07 2025-11-07/amc
Inst Owners50.31%
Inst Owner Change-0.01%
Ins Owners1.5%
Ins Owner Change9.59%
Market Cap84.07M
Revenue(TTM)N/A
Net Income(TTM)-116573000
Analysts81.82
Price Target2.72 (73.25%)
Short Float %4.39%
Short Ratio1.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.12%
Min EPS beat(2)-22.55%
Max EPS beat(2)6.32%
EPS beat(4)3
Avg EPS beat(4)7.6%
Min EPS beat(4)-22.55%
Max EPS beat(4)27.1%
EPS beat(8)5
Avg EPS beat(8)0.34%
EPS beat(12)8
Avg EPS beat(12)2.09%
EPS beat(16)9
Avg EPS beat(16)-1.22%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)18.52%
PT rev (3m)2.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.9%
EPS NY rev (1m)0%
EPS NY rev (3m)2.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.31
P/tB 1.31
EV/EBITDA N/A
EPS(TTM)-2.14
EYN/A
EPS(NY)-1.08
Fwd EYN/A
FCF(TTM)-1.98
FCFYN/A
OCF(TTM)-1.98
OCFYN/A
SpS0
BVpS1.2
TBVpS1.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -122.3%
ROE -180.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.92%
ROA(5y)-46.28%
ROE(3y)-83.34%
ROE(5y)-56.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 37.2%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.52
Quick Ratio 4.52
Altman-Z -11.62
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)208.08%
Cap/Depr(5y)2095.85%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.42%
EPS Next Y31.87%
EPS Next 2Y25.81%
EPS Next 3Y17.91%
EPS Next 5Y23.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y34.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year44.23%
EBIT Next 3Y18.82%
EBIT Next 5YN/A
FCF growth 1Y6.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.59%
OCF growth 3YN/A
OCF growth 5YN/A

ALX ONCOLOGY HOLDINGS INC / ALXO FAQ

What is the fundamental rating for ALXO stock?

ChartMill assigns a fundamental rating of 1 / 10 to ALXO.


What is the valuation status of ALX ONCOLOGY HOLDINGS INC (ALXO) stock?

ChartMill assigns a valuation rating of 0 / 10 to ALX ONCOLOGY HOLDINGS INC (ALXO). This can be considered as Overvalued.


How profitable is ALX ONCOLOGY HOLDINGS INC (ALXO) stock?

ALX ONCOLOGY HOLDINGS INC (ALXO) has a profitability rating of 0 / 10.


How financially healthy is ALX ONCOLOGY HOLDINGS INC?

The financial health rating of ALX ONCOLOGY HOLDINGS INC (ALXO) is 3 / 10.